A 42% of patients with heart failure have depression symptoms, a common co-morbidity linked to poor quality of life and a bad prognosis. In addition to having an adverse effect on everyday social and domestic activities, 1-3 depressive symptoms significantly…
Cystic fibrosis has inflammation as one of its primary pathological drivers. Current treatments are poor at controlling and halting the progression of inflammatory events, frequently made worse by concurrent infection. Using anakinra, a non-glycosylated recombinant version of IL-1Ra, offers a…
The pathophysiology of cardiovascular disease and protein-energy wasting, which are significant risk factors for morbidity and mortality in individuals with end-stage kidney disease, are linked to inflammation. Anti-cytokine therapy has been proposed to reduce inflammation and improve outcomes. Anakinra’s effectiveness,…
